press release-k8凯发
-
our company
- fosun pharma is patient-centered and clinical needs-oriented. the company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. fosun pharma improves the research and clinical development capabilities of fic (first-in-class) and bic (best-in-class) new drugs as well as accelerates the r&d and launch of innovative technologies and products.
-
our business
- fosun pharma is patient-centered and clinical needs-oriented. the company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. fosun pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. fosun pharma also vigorously explores cutting-edge technologies, such as rna, oncolytic viruses, gene therapy and protac, to enhance its innovation capabilities.
-
r&d
- guided by innovation and internationalization, the company continuously enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. fosun pharma improves the research and clinical development capabilities of fic (first-in-class) and bic (best-in-class) new drugs as well as accelerates the r&d and launch of innovative technologies and products.
-
sustainability
- fosun pharma has incorporated the sustainable development strategy into its overall development, and established a sound sustainable development management system. it has set up a corporate social responsibility management committee and an environmental, social and governance (esg) committee under the board of directors to promote the sustainable development of the group. moreover, a sound communication mechanism between stakeholders has been established to continuously improve their satisfaction, maintain its competitiveness in sustainable development, and lead the development of the industry.
-
investor relations
- founded in 1994, shanghai fosun pharmaceutical (group) co., ltd. ("fosun pharma"; stock code: 600196.sh, 02196.hk) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in china. fosun pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. as a shareholder of sinopharm group co., ltd., fosun pharma expands its areas in the pharmaceutical distribution and retail business.
-
news
- founded in 1994, shanghai fosun pharmaceutical (group) co., ltd. ("fosun pharma"; stock code: 600196. sh, 02196. hk) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in china. fosun pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. as a shareholder of sinopharm co., ltd., fosun pharma expands its areas in the pharmaceutical distribution and retail business.
-
careers
- we are looking for people that recognize and practice our cultural values, and can learn fast to create continuous value; possess profound professional knowledge of the industry, a wide vision of different regions, and global-level expertise in a certain field. we will also be committed to cultivating international top talent with outstanding performance and great potential.